Lisata Therapeutics (LSTA) vs Lantern Pharma (LTRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Lantern Pharma (LTRN) over the past year, losing 52.6% versus a loss of 81.9%. Over five years, LTRN leads with a -91.7% price change compared with -93.4% for LSTA. Lisata Therapeutics is the larger company by market cap ($13.0 million vs $12.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | LTRN |
|---|---|---|
| Share price | $1.20 | $0.83 |
| Market cap | $12.96M | $12.40M |
| 1-day change | +2.56% | -8.79% |
| YTD return | -35.48% | -72.61% |
| 1-year return | -52.57% | -81.92% |
| 5-year return | -93.44% | -91.71% |
| EPS (TTM) | $-1.64 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $4.68 |
| 52-week low | $0.99 | $0.83 |
| Distance from 52-week high | -76.33% | -82.26% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +2008.43% |
| Average volume | 291.91K | 180.42K |
| Shares outstanding | 10.80M | 14.94M |
| Employees | 21 | 16 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSTA has outperformed LTRN by 29.3 percentage points over the past year.
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Healthcare · Biotechnology · 21 employees
About Lantern Pharma
LTRN stock →Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India.
Healthcare · Biotechnology · 16 employees
LSTA vs LTRN FAQ
Which is bigger, Lisata Therapeutics or Lantern Pharma?
Lisata Therapeutics (LSTA) is larger, with a market capitalization of $12.96M compared with $12.40M for Lantern Pharma (LTRN).
Which stock has performed better over the past year, LSTA or LTRN?
LSTA returned -52.57% over the past 12 months, compared with -81.92% for LTRN (price return, excluding dividends). Past performance does not predict future results.
Are Lisata Therapeutics and Lantern Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.